Genelux Corporation/$GNLX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
- Ticker
- $GNLX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 26
- Headquarters
- Westlake Village, United States
- Website
- www.genelux.com
GNLX Metrics
BasicAdvanced
$84M
-
-$0.86
0.58
-
Price and volume
Market cap
$84M
Beta
0.58
52-week high
$6.26
52-week low
$1.77
Average daily volume
385K
Financial strength
Current ratio
2.394
Quick ratio
2.334
Long term debt to equity
0.13
Total debt to equity
0.15
Profitability
EBITDA (TTM)
-36.28
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-444,950.00%
Operating margin (TTM)
-455,275.00%
Management effectiveness
Return on assets (TTM)
-77.89%
Return on equity (TTM)
-177.93%
Valuation
Price to revenue (TTM)
9,740.933
Price to book
5.21
Price to tangible book (TTM)
5.21
Price to free cash flow (TTM)
-2.706
Free cash flow yield (TTM)
-36.96%
Free cash flow per share (TTM)
-0.695
Growth
Earnings per share change (TTM)
0.64%
3-year revenue growth (CAGR)
-91.07%
3-year earnings per share growth (CAGR)
-2.81%
GNLX Financial Performance
Revenues and expenses
GNLX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.